Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9540409 | 0.82 | LMNA (0.43) | LMNATDP1MAP4K4ALDH1A1SMN1; SMN2 | |
| SCHEMBL19965079 | 0.76 | LMNA (0.55) | LMNATDP1MAP4K4GRM5ALDH1A1 | |
| SCHEMBL11383636 | 0.75 | TERT (0.51) | ALDH1A1SMN1; SMN2KDM4EMAPT | |
| SCHEMBL10989239 | 0.75 | MAP4K4 (0.49) | MAP4K4ALDH1A1KDM4EMAPT | |
| SCHEMBL11152339 | 0.75 | MAP4K4 (0.49) | LMNAMAP4K4GRM5 | |
| SCHEMBL11149465 | 0.74 | KDM4E (0.50) | LMNATDP1MAP4K4ALDH1A1SMN1; SMN2 | |
| SCHEMBL9818059 | 0.74 | TERT (0.46) | SMN1; SMN2HTT | |
| SCHEMBL10988595 | 0.74 | TERT (0.52) | LMNATDP1MAP4K4ALDH1A1HTT | |
| SCHEMBL10708134 | 0.74 | L3MBTL1 (0.50) | ALDH1A1HTTKDM4EMAPT | |
| SCHEMBL510617 | 0.72 | ALDH1A1 (0.59) | LMNATDP1MAP4K4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507530-B2 | Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082403-A1 | PYRIDINE DERIVATIVES SUBSTITUTED BY HETEROCYCLIC RING AND PHOSPHONOAMINO GROUP, AND ANTI-FUNGAL AGENT CONTAINING SAME | ERG28, H1-2, H1-3 | LMNA 3822/4885TDP1 3169/4885MAP4K4 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.